Elevance will leave D.C. this summer and is considering other markets to depart, executives said. The company outperformed Wall Street expectations in the second quarter — but not by much, and its stock fell accordingly.
Source: Healthcare Dive
You may also like
Facing Funding Losses, States Call Out Big Businesses...
Vicarious Surgical board proposes dissolving the...
Abbott’s cancer diagnostics vision: ‘There’s...
J&J misses company expectations for cardiovascular...
SS Innovations names Sarah Romano as CFO
Judge tosses another No Surprises lawsuit against...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.